Medline Inc. (MDLN) AI Stock Analysis

Medline Inc. manufactures med-surg products serving hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes domestically and internationally. The company operates through two segments: Medline Brand and Supply Chain Solutions. Medline Brand procures and manufactures products across surgical solutions, front line care, and laboratory and diagnostics, offering items such as wound care, exam gloves, surgical procedure trays, drapes, gowns, and vital signs monitors. The Supply Chain Solutions segment procures and distributes third-party products from national brands while providing logistics and supply chain optimization services.

Medline grew annual revenue from $21.45B in FY2022 to $23.23B in FY2023, $25.51B in FY2024, and $28.43B in FY2025, achieving a 9.9% 3-year revenue CAGR. Gross margin expanded from 21.2% in FY2022 to 22.5% in FY2023, 24.7% in FY2024, and 26.4% in FY2025. Operating margin was 4.1% in FY2022 and 7.8% in FY2025, while net income shifted from -$25.0M in FY2022 to $1.16B in FY2025. Over the trailing twelve months, revenue reached $29.94B with an operating margin of 0.8% and a net profit margin of 2.3%. For the latest quarter ended June 30, 2026, quarterly revenue increased 11.6% year-over-year and quarterly earnings grew 262.0%.

As of June 30, 2026, Medline held $2.68B in cash and short-term investments against total debt of $12.64B, resulting in net debt of $9.96B and a debt-to-equity ratio of 1.09. Liquidity is supported by a current ratio of 4.33, with shareholders' equity standing at $11.57B. In FY2025, operating cash flow was $1.74B and free cash flow reached $1.30B. The company allocated capital toward $447.0M in capital expenditures, $2.00B in share buybacks, and $518.0M in dividends paid during FY2025.

At a last close of $35.96 on October 16, 2026, Medline holds a market capitalization of $48.38B and an enterprise value of $40.06B. Medline trades at a trailing P/E of 89.9x and a forward P/E of 20.9x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its EV/EBITDA stands at 14.6x compared to 12.0x for peer group medians, while its price-to-sales ratio of 1.6x sits below the peer median of 4.1x. The stock has posted a year-to-date return of -14.4%, while the S&P 500 (SPY) returned 16.8% over the past year.

Wall Street coverage on Medline consists of 16 Strong Buy, 7 Buy, and 4 Hold ratings, with 0 Sell and 0 Strong Sell recommendations. The mean price target is $44.42, representing a 23.5% upside compared to the last close of $35.96. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $31.23B and EPS of $1.54, implying 17.0% EPS growth. The company has beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Medline Inc. (MDLN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MDLN income statement, MDLN balance sheet, MDLN key metrics, MDLN analyst forecast, MDLN chart. See the MDLN stock overview for the latest quote and news.